Macrogenics (MGNX) Free Cash Flow (2012 - 2026)
Macrogenics (MGNX) reported Free Cash Flow of -$36.1 million for Q1 2026, up 23.9% year-over-year from -$29.1 million in Q1 2025, and down 184.36% quarter-over-quarter from $42.8 million in Q4 2025.
Macrogenics (MGNX) Free Cash Flow (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Free Cash Flow data on file, last reported at -$36.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$36.1 million, up 23.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$71.6 million (up 1.07% YoY), and the FY2025 annual result was -$83.0 million, down 15.09% from the prior year.
- Free Cash Flow slipped to -$36.1 million in Q1 2026 per MGNX's latest filing, from $42.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $59.6 million in Q3 2024 and troughed at -$59.1 million in Q1 2022.
- A 5-year average of -$21.3 million and a median of -$36.1 million in 2026 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 264.5% in 2024 and fell as far as 2079.03% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $26.0 million in 2022, then sank by 210.25% to -$28.7 million in 2023, then sank by 36.19% to -$39.0 million in 2024, then surged by 209.61% to $42.8 million in 2025, then slumped by 184.36% to -$36.1 million in 2026.
- Business Quant data shows MGNX's Free Cash Flow at -$36.1 million in Q1 2026, $42.8 million in Q4 2025, and -$30.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -36.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.09 Mn |
| Mar 31, 2026 | -36.09 Mn |
| Dec 31, 2025 | 42.78 Mn |
| Dec 31, 2025 | 42.78 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -47.70 Mn |
| Jun 30, 2025 | -47.70 Mn |
| Mar 31, 2025 | -47.42 Mn |
| Mar 31, 2025 | -47.42 Mn |
| Dec 31, 2024 | -39.03 Mn |
| Dec 31, 2024 | -39.03 Mn |
| Sep 30, 2024 | 59.57 Mn |
| Sep 30, 2024 | 59.57 Mn |
| Jun 30, 2024 | -45.52 Mn |
| Jun 30, 2024 | -45.52 Mn |
| Mar 31, 2024 | -47.10 Mn |
| Mar 31, 2024 | -47.10 Mn |
| Dec 31, 2023 | -28.66 Mn |
| Dec 31, 2023 | -28.66 Mn |